Purple Book product · Reference 351(a)

Prolia

denosumab

351(a)BLA 125320RxLicensed Amgen Inc.

View denosumab family Open on FDA Purple Book

At a glance

Jun 01, 2010

Approved

Reference 351(a)

License type

Marketing

Yes

Patents listed

Key dates

Approval
Approval date of this BLA submission.
Jun 01, 2010
16 yr 3 mo ago
Today

Pharmaceutical detail

Strength

60MG/ML

Dosage form

Injection

Route

Subcutaneous

Presentation

Pre-Filled Syringe

Center

CDER

License number

1080

Product number

001

Submission type

Original

Supplement number

Not listed

Change type

Not listed

Reference product family

View full family

This is the reference (originator) product. Biosimilars and interchangeables referencing it are listed below.

Patent list (57)

Patents published in the FDA Purple Book Patent List for this product, with expiration date and source link.
Patent	Expires	In	Source
8,058,418	Nov 30, 2023	2 yr 7 mo ago	FDA
7,364,736	Feb 19, 2025	1 yr 4 mo ago	FDA
7,427,659	Mar 15, 2025	1 yr 3 mo ago	FDA
8,247,210	Dec 06, 2026	in 6 mo	FDA
8,460,896	Dec 06, 2026	in 6 mo	FDA
8,680,248	Dec 06, 2026	in 6 mo	FDA
8,217,153	Jan 05, 2027	in 7 mo	FDA
7,928,205	Feb 12, 2027	in 8 mo	FDA
7,888,101	Apr 06, 2027	in 10 mo	FDA
7,662,930	Apr 24, 2027	in 11 mo	FDA
9,359,435	May 22, 2027	in 1 yr	FDA
8,053,236	Jan 19, 2030	in 3 yr 8 mo	FDA
9,228,168	Jan 19, 2030	in 3 yr 8 mo	FDA
9,320,816	Nov 14, 2030	in 4 yr 6 mo	FDA
9,012,178	Aug 05, 2031	in 5 yr 3 mo	FDA
9,133,493	Apr 20, 2032	in 6 yr	FDA
9,388,447	Apr 20, 2032	in 6 yr	FDA
11,292,829	Jun 29, 2032	in 6 yr 2 mo	FDA
11,634,476	Jun 29, 2032	in 6 yr 2 mo	FDA
11,685,772	Jun 29, 2032	in 6 yr 2 mo	FDA
9,371,554	Dec 14, 2032	in 6 yr 8 mo	FDA
11,293,930	Mar 26, 2033	in 6 yr 11 mo	FDA
11,486,883	Mar 26, 2033	in 6 yr 11 mo	FDA
9,328,134	Feb 20, 2034	in 7 yr 10 mo	FDA
11,319,568	Mar 10, 2034	in 7 yr 11 mo	FDA
11,459,595	Mar 10, 2034	in 7 yr 11 mo	FDA
11,952,605	Mar 10, 2034	in 7 yr 11 mo	FDA
12,084,686	Mar 10, 2034	in 7 yr 11 mo	FDA
11,492,372	Mar 11, 2034	in 7 yr 11 mo	FDA
10,421,987	May 29, 2034	in 8 yr 1 mo	FDA
10,894,972	May 29, 2034	in 8 yr 1 mo	FDA
11,434,514	May 29, 2034	in 8 yr 1 mo	FDA
11,946,085	May 29, 2034	in 8 yr 1 mo	FDA
9,481,901	May 29, 2034	in 8 yr 1 mo	FDA
9,803,166	Sep 29, 2034	in 8 yr 5 mo	FDA
11,299,760	Oct 30, 2034	in 8 yr 6 mo	FDA
10,513,723	Dec 09, 2034	in 8 yr 8 mo	FDA
11,254,963	Dec 09, 2034	in 8 yr 8 mo	FDA
10,106,829	Dec 11, 2034	in 8 yr 8 mo	FDA
10,227,627	Dec 11, 2034	in 8 yr 8 mo	FDA
10,655,156	Dec 11, 2034	in 8 yr 8 mo	FDA
10,907,186	Dec 11, 2034	in 8 yr 8 mo	FDA
11,130,980	Apr 05, 2035	in 9 yr	FDA
11,077,404	May 13, 2035	in 9 yr 1 mo	FDA
11,384,378	Jun 04, 2035	in 9 yr 2 mo	FDA
11,427,848	Jun 04, 2035	in 9 yr 2 mo	FDA
10,583,397	Jul 28, 2035	in 9 yr 3 mo	FDA
11,786,866	Oct 21, 2035	in 9 yr 6 mo	FDA
11,192,919	Nov 13, 2035	in 9 yr 7 mo	FDA
10,167,492	Dec 01, 2035	in 9 yr 8 mo	FDA
10,822,630	Dec 01, 2035	in 9 yr 8 mo	FDA
11,275,090	Jul 02, 2037	in 11 yr 3 mo	FDA
11,098,079	Jul 21, 2037	in 11 yr 4 mo	FDA
9,881,367	Aug 09, 2037	in 11 yr 4 mo	FDA
12,025,618	Aug 26, 2039	in 13 yr 5 mo	FDA
11,744,950	Nov 21, 2039	in 13 yr 8 mo	FDA
12,059,555	Sep 02, 2040	in 14 yr 5 mo	FDA

Taxonomy and ontology

11 terms

center

Center for Drug Evaluation and Research

center · CDER

application pathway

Biologics License Application

blaNumber · BLA

license type

351(a)

blaType · 351(a)

application pathway

Section 351(a) Biologic

blaType · 351(a)

product role

Reference or Standalone Biologic

blaType · Reference product

marketing status

Prescription

marketingStatus · Rx

licensure status

Licensed

licensure · Licensed

route

Subcutaneous

routeOfAdministration · Subcutaneous

dosage form

Injection

dosageForm · Injection

source kind

Monthly Download

sourceKind · monthly_download

Food and Drug Administrationparent ofCenter for Drug Evaluation and Research
Food and Drug Administrationsource forMonthly Download
Biologics License Applicationparent ofSection 351(a) Biologic
Biologics License Applicationparent ofSection 351(k) Biosimilar or Interchangeable
Section 351(a) Biologicmaps to351(a)
351(a)classifiesReference or Standalone Biologic

Source provenance

Source kind · Monthly download

Checked May 28, 2026

FDA release · April 2026

FDA source FDA source

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.

Book a Demo